In 2010 Entrepreneur Jim Tananbaum founded Foresite Capital in the San Franciso Bay area. He is the Chief Executive Officer of the company which invests in private equity firms involved in the healthcare industry. Tananbaum and his team identify emerging companies that they want to invest in and then help those companies grow by providing capital, information, and their network of other industry experts.
Prior to founding Foresite Capital, Jim Tananbaum co-founded two other companies that invested in healthcare companies. He had also co-founded two biotechnology companies previously in his professional career. One of his companies, GelTex Pharmaceuticals, had two drugs approved by the FDA. HE sold the company for $1.6 billion in 1998 after one of his drugs, Renagel, started producing more than $200 million a year in revenue. His other company, Theravence, Inc., has also proven to be very successful and, along with their partner Innoviva, is now worth $3.2 billion.
Jim Tananbaum has a Partner at Sierra Ventures and put in place this investment company’s healthcare services investment policy. He also led Prospect Venture Partners, another healthcare investment company, for nine years as the Managing Director. This company invested in biotechnology startups.
Tananbaum’s leadership at Foresite Capital has led to their investing in 77 healthcare companies. This includes those that create pharmaceuticals as well as medical services, genomics sequencing, and diagnostic services. His largest and most notable investments have been in Aerie Pharmaceuticals, Intarcia Therapeutics, and 10X Genomics.
As a scientist, Jim Tananbaum has said that in the near future doctors will be able to catch diseases in the earliest stages when they are most treatable by sequencing blood, tissue, and/or saliva that is taken from patients. Genomic sequencing like this will lead to people leading longer, healthier lives.
As an entrepreneur, Jim Tananbaum said that he spends quite a bit of time doing his due diligence before making an investment in a healthcare company. Even though every investment has by its nature an element of risk he finds that operating this business leads to good returns rather than a loss more often than not.